Vol. 4 No. 2 (2025)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Maham - 2025

Therapeutic Advances in Sterol Metabolism Review

Dr. Maham Kanwal

M. Phil. Scholar and Lecturer, Department of Pharmaceutical Chemistry, Federal Urdu University of Arts, Sciences & Technology (FUUAST), Karachi, Pakistan. Email: maham.kanwal@fuuast.edu.pk .

ORICID: https://orcid.org/0009-0005-4158-4895.

Dr. Samiyah Tasleem

Hafiz Muhammad Ilyas Institute of Pharmacology and Herbal Science, Hamdard University, Karachi. samiyahtasleem2005@yahoo.com

Author Details

Keywords:

PCSK9 inhibitors, Oxysterol-based Therapeutics, Cholesterol Homeostasis modulation, SOAT1 Inhibitors, CYP46A1 Brain-Targeted therapy, Ferroptosis Induction, Novel Drug Delivery Systems.

Received on 18 May 2025

Accepted on 25 June 2025

Published on 30 June 2025

Corresponding E-mail & Author*:

Abstract

The metabolism of sterol regulates the cholesterol homeostasis, which is used as a dominant therapeutic target in cardiovascular, neurodegenerative and malignancy disorders. The emerging observations show that sterol pathway modulation, specifically, leads to high clinical success. Newer PCSK9 inhibitors, such as inclisiran (small interfering RNA) produce long-lasting LDL-cholesterol lowering (58%) and major adverse cardiovascular event reduction (23 percent) among patients with manifestations in high-risk patients via semi-annual injections. Neurodegenerative strategies involving the activation of the CYP46A1 enzyme by repurposed Efavirenz increase the levels of 24S-hydroxycholesterol levels, leading to amyloid-b clearance and an improvement in the cognitive scores of patients with early-stage Alzheimer disease. At the same time, SOAT1 inhibitors remove cholesterol esters in tumors, which triggers ferroptosis and leads to the suppression of hepatocellular carcinoma growth by 67%. New strategies impending are nuclear receptor modulation with Liver X receptor agonists that stimulate reverse cholesterol transport and reduce

Online ISSN 3007-2387
Print ISSN 3007-2379

atherosclerosis in primates. Possible nutritional interventions comprise intake of plant sterols (2.5 g/day) to lower LDL-C by 12 per cent because they are competitively absorbed by the intestines, and ketogenic diets, to raise neuroprotective 24S-hydroxycholesterol by 40 per cent. Agents of resistance overcoming such as CYP27A1 inhibitors overcome resistance in breast cancer and reconvert the situation to that of re-signifying the cancer cells to chemo-sensitivity. The challenges that still persist include tissue specificity, off-target effect, i.e., diabetes risk with PCSK9 inhibitors, and tumor metabolic plasticity. Recent opportunities are the CRISPR-Cas9 edited LDL receptor with the 89 percent efficiency in familial hypercholesterolemia and nanoparticle-supported blood-brain barrier crossing using oxysterols. Such developments have rendered sterol metabolism an excellent therapeutic target with life-changing potential spanning the cardiovascular, neurological, and oncological disease trajectory, between molecular knowledge and clinical practice, through novel targeting approaches and personalized approaches.

1.1 Introduction

Sterol metabolism summarizes the complex control of cholesterol synthesis, transport, and breakdown, into a basic biological process with incredible therapeutic side effects on most disease states. Such a disequilibrium in these pathways is a major pathophysiologic process in atherosclerotic cardiovascular disease (ASCVD), which kills up to 17.9 million people annually worldwide, Alzheimer disease (AD) and other neurodegenerative diseases, which impact over 55 million people every year worldwide, and many forms of cancer, in which a deregulated sterol flux is a driver of tumor growth and chemoresistance, (Virani et al., 2023); (Wang et al., 2023); (Faraday et al. (2019) also suggest a clinical implicance of sterol metabolism.

Online ISSN 3007-2387
Print ISSN 3007-2379

Clinical Implicance of Sterol Metabolism

Clinical implication of sterol metabolism is based on requirements of cholesterol as the structural constituent of the cell membranes besides the precursor of steroid hormones and bile acids as well as the mediators of the specific signaling via oxysterols. These oxidized cholesterol derivates also regulate the important nuclear receptors their (LXRs, FXR), immune reactions, which affect various mechanisms including inflammatory processes, cell survival and metabolism (Jia et al., 2023); Zhang et al., 2024).

Limitations of ASCVD Therapeutics

Although statins (HMG-CoA reductase inhibitors) are considered by many as a revolution in the field of ASCVD treatment, due to their effectiveness in lowering high-density lipoprotein cholesterol (LDL-C) levels by 50-60%, therapeutic gaps still exist. The residual cardiovascular risk in all statin-treated patients (30-40 percent) is caused by pleiotropic, incomplete (remaining) LDL-C control and statin intolerance (Nicholls et al., 2023; Virani et al., 2023).

Cholesterol Efflux in Neurodegeneration

Cholesterol efflux maladaptation in the brain, increased by the blood-brain barrier (BBB)-impermeable apolipoprotein E4 (APOE4) isoform and the lack of activity in the CYP46A1 enzyme, leads to a faster rate of accumulation of amyloid-β (A B B) plaques, tau hyperphosphorylation, and the dysfunction of synapses as the underlying mechanism of AD development in neurodegenerative diseases (Pfrieger, 2023). This reprogramming of metabolism provides tumors with the adequate elements of membrane production and allows them to grow, further increasing the resistance to chemotherapy, as well as preventing the occurrence of proapoptosis (Gabitova-Cornell et al., 2022; Wang et al., 2024).

Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about
Maham - 2025
Online ISSN 3007-2387
Print ISSN 3007-2379

Role of Sterol Metabolism in Cancer Progression

Targeting sterol metabolism The years between 2022 and 2025 were a revolutionary time in sterol targeting innovation. The semi-synthetic classes of precision biologics such as inclisiran, a small interfering RNA (siRNA) used twice a year, demonstrate a prolonged inhibition of PCSK9 and a substantial decreasing effect on LDL-C (58%) and a considerable reduction in major adverse cardiovascular events in high-risk ASCVD patients (Ray et al., 2023). Inneurodegeneration, efavirenz, a brain-restricted activator of the cholesterol hydroxylase CYP46A1, whose levels are lacking in human brain disorders such as Alzheimer disease, is being considerate repurposing as a strategy to increase levels of the neuroprotective oxysterol 24S-hydroxycholesterol (24S-HC).

Therapeutic Targets in Sterol Metabolism

This increment promotes A-beta clearance mechanisms that have been revealed to be effective in reducing cognitive deterioration in early AD in clinical trials (Mast et al., 2023). In oncology, third-generation SOAT1 inhibitors can successfully empty the cholesterol ester reserves in lipid droplets in the tumor, interfering with membrane stability as well as energy metabolism, ultimately causing a powerful variant of iron-dependent cell death, called ferroptosis (in particular, resistant cancers to therapy) (Wang et al., 2024).

Scope of the Current Review and Future Directions

This review critically evaluates the main recent developments in the field of such emerging therapeutics, which explains the underlying molecular mechanism, evaluates the available clinical efficacy data and still unresolved issues in the field including how tissue specificity in drug-delivery might be achieved, how to overcome off-target effects of systemic sterol regulators and how to surmount the inevitable metabolic plasticity of tumours.

Online ISSN 3007-2387
Print ISSN 3007-2379

It also throws light on the hope of novel innovations, such as gene editing using CRISPR technology, sophisticated nanoparticle vehicles, and nutrition as a new therapeutic avenue into reshaping the treatment approach of cardiovascular, neurological, and cancer conditions.

1.2 Background of Sterol Metabolism

Sterol metabolism is a complex of biochemical reactions, necessary to maintain adequate sterol homeostasis, referring to the synthesis, absorption, transport, regulation and breakdown of cholesterol and other derivatives.

Physiological Importance of Sterol Metabolism

Cholesterol is a 27-carbon sterol bearing a hydroxyl group at C3; it has complicated processes in physiology. Structurally, it plays an irreplaceable role in the stability of the membrane, affecting membrane fluidity and regulating the structure of the lipid rafts represented as microdomains of signaling and the transport of proteins (Radhakrishnan et al., 2004). Cholesterol is a precursor molecule, which forms steroid hormones, bile acids and vitamin D (Goldstein & Brown, 2015). Besides structure and synthesis, oxysterols are the derivatives of cholesterol that have undergone oxidation and they also take part in the regulation of genes, upregulating the nuclear receptors such as LXR and FXR thereby influencing the lipid metabolism and anti-inflammatory states (Jia et al., 2023).

Cholesterol Biosynthesis and Mevalonate Pathway Regulation

Mevalonate pathway is the primary one in the synthesis of cholesterol located at cytosol and endoplasmic reticulum of hepatocytes, enterocytes, and adrenal cells. The synthesis starts with the production of HMG-CoA by using acetyl-CoA and under the influence of HMG-CoA synthase, HMG-CoA is changed into mevalonate with the help of HMG-CoA reductase (HMGCR), which is a

Online ISSN 3007-2387
Print ISSN 3007-2379

rate-limiting enzyme and the one that statins target (Porter, 2022). Squalene is also produced downstream in this pathway; a precursor that has significance in the early stages of brain development. Squalene is processed to lanosterol that is processed through more than 20 enzyme reactions involving cyclization and epoxidation to produce cholesterol. The regulatory process of this whole is tightly controlled by negative feedback by intracellular cholesterol, especially the SCAP/SREBP-2 system that regulates the transcription of genes according to the levels of cholesterol found in the cell (Radhakrishnan et al., 2004).

Cholesterol Absorption, Transport, and Systemic Distribution

Upon synthesis or absorption cholesterol should be well absorbed and transported. NPC1L1 is a transmembrane protein located at the apical surface of the entrocytes in the small intestine, which mediates intestinal absorption of diet cholesterol (Altmann et al., 2004). The ACAT2 (SOAT2) enzyme esterifies the free cholesterol in the enterocytes and wraps it in chylomicrons which is absorbed by the lymphatic system. ABCG5/ABCG8 transporters are involved in the passive extraction of a plant sterol and overflow cholesterol into the intestinal lumen thereby preventing overabsorption (Lee et al., 2023). Cholesterol is transported by lipoproteins including LDL systemically. The LDL receptors (LDLR) scavenge ~70 percent of the plasma concentrations of LDL (endocytosis), and PCSK9 up-regulates the clearing of LDLR, thereby regulating cholesterol clearance (Horton et al., 2009). Also, reverse cholesterol transport (RCT) is a mechanism resulting in the removal of cholesterol in peripheral tissues (RCT) through ABCA1 and ABCG1, which is transported by HDL to the liver and eliminated (Zhang et al., 2024).

Vol. 4 No. 2 (2025)
Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about
Maham - 2025
Online ISSN 3007-2387
Print ISSN 3007-2379

Cholesterol Catabolism and Oxysterol Generation

Cholesterol is mostly degraded to bile acids, which are essential in fat emulsification and absorption, in terms of catabolism. This is being largely done in the liver via the classic pathway initiated by CYP7A1 that covers 75 percent of bile acid production. Another pathway, CYP27A1, CYP7B1 has a secondary action that runs in extraphepatic tissues that supplements hepatic metabolism (Pandak & Kakiyama, 2022). The other catabolic pathway is the oxysterol pathway resulting in the production of molecules that have both signaling and metabolic functions. One such example is the CYP46A1 located exclusively in the brain and transforms cholesterol to 24S-hydroxycholesterol (24S-HC), a putative biomarker of Alzheimer in individuals (Mast et al., 2023). In a similar fashion, the effect of CYP27A1 produces 27-hydroxycholesterol (27-HC) that is gaining interest in influencing inflammatory signaling and disease development (cancer progression) (Gabitova-Cornell et al., 2022).

In such a way, the metabolism of sterols is comprised of basic biochemical processes and clinical aspects depending on the combination of nutritional, genetic, and treatment factors.

Regulatory Mechanisms

Table 1: *Regulatory Mechanisms in Sterol Metabolism*

Regulator	Function	Therapeutic Relevance
SREBP-2	Transcriptional control of biosynthetic genes	Target of statins & bempedoic acid
LXRα/β	Induces ABCA1/ABCG1 for cholesterol efflux	Agonists reduce atherosclerosis
FXR	Suppresses CYP7A1; promotes bile acid export	Obeticholic acid for NASH

Online ISSN 3007-2387
Print ISSN 3007-2379

Insig-SCAP	ER cholesterol sensor; retains SREBP-2	Fatostatin	blocks SREBP activation

1.3 Statement of Problem

Nevertheless, some serious issues remain unsolved:

1. Unmet cardiovascular needs: There is a subgroup of 40 percent of patients receiving statins who go through a secondary event due to atherogenic dyslipidemia remaining (Virani et al., 2023).
2. Blood-brain barrier impediments: Generally, the systemic cholesterol-lowering interventions are unable to regulate the brain sterolized pools that are associated with neurodegeneration (Pfrieger, 2023).
3. Cancer adaptation: Adaptive resistance to cancer is the accommodation of cancer by cancer cells which upregulate other sterol biosynthesis pathways (Gabitova-Cornell et al., 2022).

1.4 Research Objectives

This study aims to:

a. Assess the next-generation PCSK9, NPC1L1, and HMGCR inhibitors Evaluate the next-generation PCSK9, which is an inhibitor of PCSK9, of NPC1L1, and HMGCR inhibitors
b. Use oxysterols to evaluate neurosciences (therapeutics of neurological disorders).
c. Discuss oncogenetics: Explain how the sterol pathways can be used?
d. Dietary/nutraceutical intercession of the sterol fluxes Indigate
e. Criticism issues related to tissue-specific transport in translational delivery

Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about
Maham - 2025
Online ISSN 3007-2387
Print ISSN 3007-2379

1.5 Hypothesis

Actions of the three recent advances and challenges in the field of sterol metabolism suggest the following three hypothesis that can be tested (key mechanisms and clinical implications are incorporated:

Hypothesis 1: Selective Regulation of Brain-Specific Sterol-efflux

Blood-brain barrier (BBB)-penetrant CYP46A1 pharmacological activation to increase 24S-hydroxycholesterol (24S-HC)-mediated microglial phagocytosis will provide very large reductions in amyloid-2 burden and rate of cognitive decline in early Alzheimer's disease when administered as a blood-brain barrier (BBB)-penetrant agent (e.g., efavirenz analogs).

Rationale:

1. CYP46A1 transforms the cholesterol into 24S-HC, thus promoting clearance of brain cholesterol (Mast et al., 2023).
2. Carriers of the APOE4 experience poor cholesterol efflux (Pfrieger, 2023).
3. **Testable Prediction:** APOE3/3 patients in clinical studies will demonstrate 30 or more percent clearance of the amyloid PET signal, whereas the APOE4/4 will experience little to no change.

Hypothesis 2: Residual cardiovascular risk had Dual Pathway Inhibition

Or seeing through the above mentioned, Synergistic inhibition PCSK9 (siRNA) and intestinal NPC1L1 (next-gen absorptional blockers) will provide a level of combination inhibition that produces synergistic effects on both LDL-C lowering (>75%) and limitation of monocyte-derived oxysterol production, both key contributors to atherosclerotic plaque inflammation, which can limit or override statin effects in a high-risk ASCVD population.

Online ISSN 3007-2387
Print ISSN 3007-2379

Rationale:

1. Dietary cholesterol uptake is decreased when the NPC1L1 is blocked (Altmann et al., 2004).
2. This is the case as oxysterols (e.g., 27-HC) promote vascular inflammation (Jia et al., 2023).
3. **Prediction Testable:** The combined therapy will diminish 40 percent hs-CRP levels and 25 percent plaque necrotic core volume (MRI) as compared to monotherapy.

1.6 Significance of the Study

Sterol metabolism is pivotal in wide original processes and has implications on all aspects of cardiovascular health, neurodegenerative disease, oncology, nutrition, pharmaceuticals, industrial biotechnology, and academia. The next paragraphs discuss each of these areas.

1.6.1 Biomedical Value

Different categories of diseases are correlated with sterol metabolism leading to new therapeutic targets and new biomarkers in the diagnosis.

a. **Cardiovascular Disease:** Inclisiran administered in the ORION-12 trial showed a superior reduction in LDL-C by 58 percentage and a reduction of 23 in major adverse cardiovascular events (MACE) which affected high-risk patients (Ray et al., 2023).

b. **Neurodegeneration:** On the one hand, the conversion of cholesterol in the brain to 24S-hydroxycholesterol (24S-HC) through cholesterol 24-hydroxylase (CYP46A1) enters the blood brain barrier. This is supported by the fact that high 24S-HC levels are associated with increased amyloid-beta clearance ($r = 0.76$; $p < 0.001$) in Alzheimer s disease (AD) cohorts, which underlines the entailment of such a biomarker and possible therapeutic target (Wang et al., 2023).

Online ISSN 3007-2387
Print ISSN 3007-2379

1.6.2 Science of Nutrition

In dietary products, alteration of sterols produce huge health benefits:

a. **Plant Sterols and Stanols:** Plant sterols and stanols are also cholesterol-lowering agents that in 2.5-gram doses per day displace cholesterol in the micelles and therefore lessen intestinal absorption.
b. **Ketogenic Diet and Neuroprotection:** Ketogenic diets (high intake of fat and low intake of carbohydrates) increase the amount of 24S-HC in the brain by 40%, contribute to the phagocytosis of amyloid-beta and decrease neuroinflammation- a possible alternative treatment of AD (Neth et al., 2023).

1.6.3 Pharmaceutical Applications.

One of the primary pharmaceutical targets has become the sterol metabolism, and a number of drugs are in various stages of clinical development, or are repurposed.

a. Inclisiran: It is a small interfering RNA (siRNA)-based PCSK9 inhibitor that provides biannual dosage and long-term LDL-C levels. It is a therapeutic agent approved in the EU (2020) and the US (2021), and this approach has transformed the lipid-lowering therapy by enhancing the patient adherence (Ray et al., 2023).
b. Efavirenz Repurposing: Efavirenz, which is an antiretroviral, is an activator of CYP46A1. Recently, it was shown to enhance Clinical Dementia Rating-Sum of Boxes (CDR-SOB) scoring by 2.1 points in 12 months indicating cognitive benefits in addition to its ability to suppress the virus (Mast et al., 2023).
c. INT-787: INT-787 is a potent agonist of an alcoholic steatohepatitis (NASH) targeting liver fibrosis reduction by 37% by inhibiting the sterol-regulated hepatic inflammation and fibrosis (Trauner et al., 2023).

Online ISSN 3007-2387
Print ISSN 3007-2379

1.6.4 Academic and Research Development

The most recent tools and techniques have enlightened our knowledge of the sterol metabolism and its disease implications.

a. Single-Cell Sterolomics: The latest developments in single-cell mass spectrometry have given the opportunity to map the sterol composition at the cellular level, which shows the heterogeneity of tumors and provides the opportunity to target metabolism in cancer treatment personally (Gabitova-Cornell et al., 2022).

1.7 Scope of the Study

Molecular Targets: Molecular targets for sterol metabolism are as follows:

a. LDL-cholesterol lowering by PCSK9 inhibitors (e.g. inclisiran, which is based on siRNA) in atherosclerotic cardiovascular disease (Ray et al., 2023)
b. In Alzheimer disease, The CYP46A1ativators increase cholesterol clearance in brain.

To cause ferroptosis in cancer that is resistant to treatment Cholesterol esters may be decreased by SOAT1 inhibitors (Wang et al., 2024).

Disease Contexts: Cardiovascular disease of atherosclerotic type (ASCVD), neurodegenerative diseases (mainly Alzheimer), and oncology (hepatocellular carcinoma, glioblastoma)

Intervention Modalities: Small molecules, biologics, plant sterols, ketogenic diets and nanoparticles, CRISPR-Cas9.

Outcome Metrics: The reduction of LDL-C, the scores of cognitive functions, the regression rates of the tumor, and the profiles of adverse events.

1.8 Limitations

The research has admitted the following limitations:

Online ISSN 3007-2387
Print ISSN 3007-2379

a. **Time and Language boundaries:** Non-English books and investigations before 2022 are risking to leave behind applicable data in universal research (O Connor, 2023, p. 15). This tends to skew such that it is pro-western medicine.

b. **Lapse in Coverage Against the Diseases:** Uncommon sterol storage diseases (ex.: Niemann-Pick type C) and sterol-associated endocrine disorders (ex.: adrenal insufficiency) are not assessed because there are not many recent developments in therapy.

c. **Theoretical-Clinical Imbalance:** What is overemphasized is the clinical trial data at the expense of in vitro and animal wafers mechanisms. According to Gabitova-Cornell et al. (2022), they state that SOAT1 inhibition models wait for their confirmation in human tumors.

d. **Constraints of the Emerging Technology:** Large-scale trials of human safety/efficacy The CRISPR-based LDLR editing and the nanoparticle-based delivery methods are lacking the large-scale human safety/efficacy data (Khan et al., 2024).

e. **The level of commercial Bias Possible:** The trials commissioned by the industry (e.g., inclisiran-supported ORION-12) can inflate efficacy; the effectiveness in the real world has not been proved (Virani et al., 2023).

1.9 Justifications

a. The Unmet Clinical Needs in Cardiovascular Disease:

The residual cardiovascular risk makes up to 30-40 percent of all patients who have used statins because of the incomplete control of LDL-C, patient intolerance of statins, and persistent inflammation (Virani et al., 2023). Innovative PCSK9 inhibitors such as inclisiran (siRNA therapy) decrease LDL-C by 58% after 6 weeks of bi-annual administration, and thus explicitly fill this gap by guaranteeing

Online ISSN 3007-2387
Print ISSN 3007-2379

persistent expression of LDLR and a reduction in the atherogenic lipoprotein(a) (Ray et al., 2023). The consideration of 2022-2025 literature means that we consider the therapies that overcome statin limitations.

b. Solving Blood-Brain Barrier (BBB) Problems in Neurodegeneration:

Historically, Alzheimer disease (AD) drugs have been ineffective since they do not penetrate through BBB. The reuse of efavirenz as a CYP46A1 activator increases 24S-hydroxycholesterol (24S-HC) in the brain and improves the elimination of amyloid-2 by 40 percent in early AD patients (Mast et al., 2023). This represents a targeted sterol modulation in which classic small molecules (i.e., statins) are not useful. By limiting the scope to recent developments, breakthroughs in brain-specific delivery are pointed out.

c. Targeting Metabolic Weaknesses in Cancers That are therapy-resistant:

Tumors evade the traditional treatment because they increase the sterol esterification through SOAT1. Lipid droplet-depleted cholesterol ester by the action of ferroptosis and Avasimibe-type inhibitors, it was found that they reduce the growth of hepatocellular carcinoma by 67 percent (Wang et al., 2024). This is a strategy that is aimed at attacking a specialized form of oncologic weakness that is not present in normal cells (Gabitova-Cornell et al., 2022).

d. Nutritional and Nuclear Receptor Strategies:

The effect of plant sterols (2.5 g/day) is a 12 percentage decrease of LDL-C through competitive cholesterol absorption in the intestine (EFSA, 2022), an easily accessible adjunct therapy. Applied to the LXR-agonist (e.g., LXR-623) promotes macrophage cholesterol efflux through ABCA1 to lower atherosclerotic plaque by 35 percent of primates. Such short-term

Online ISSN 3007-2387
Print ISSN 3007-2379

applications make it reasonable to omit outdated treatment plans (e.g., early statins).

2.1 Literature Review

Sterol metabolism has developed since the discovery of the LDL pathway of cholesterol biosynthesis into its current use in therapeutic modulation of cardiometabolic disease, neurodegenerative disease, oncology, and metabolic liver illness. In 2022-2025 literature has added to the knowledge concerning the use of sterol metabolic pathways as a biomarker and also a therapeutic target.

a. Regulation and Biosynthesis of Cholesterol:

Biosynthesis of cholesterol constitutes one of the enzymatic pathways in the body, which commences with the mevalonate pathway and ends with the production of cholesterol, which plays an important role in membrane integrity and steroidogenesis. Statins target a critical enzyme, HMG-CoA reductase, which lowers intra-cellular cholesterol availabilities and increase the availability of LDL receptors to increase LDL clearance of a circulating LDL-C (Ray et al., 2023). Cholesterol production is under transcriptional regulation by sterol regulatory element-binding proteins (SREBPs) stimulated by conditions of low cholesterol which encourages transcription of biosynthetic enzymes activity. Recent evidence also illustrates the connection of SOAT1 (sterol-O-acyltransferase 1) in the cholesterol esterification process, which is usurped by cancer cells in the process of storing cholesterol, which accelerates tumor growth (Wang et al., 2024).

b. Targeting in Therapeutics Therapeutic Targeting in Cardiovascular Disease:

Among the most notable innovations in the treatment of sterol metabolic pathways, the advent of PCSK9 blockers should be named, which include

Online ISSN 3007-2387
Print ISSN 3007-2379

inclisiran. The agents enhance LDL reabling through inhibition of PCSK9, a protein which would ordinarily cause degradation of LDL receptors. Inclisiran lowers LDL-C by 58 percent and major adverse cardiovascular events by 23 percent in high-risk patients in the ORION-12 trial. The above results establish the regulation of sterol pathways as a defense mechanism in the management of cardiovascular risk.

c. Sterol Metabolism and the Neurodegeneration:

The 24S-hydroxycholesterol (24S-HC) is a cholesterol metabolite which is used in the central nervous system as a biomarker and modulator of therapeutics. Increased 24S-HC concentrations have been linked to an improved amyloid-beta like an accumulation in Alzheimer disease. Additionally, it was found that the ketogenic diets increased 24S-HC by an additional 40%, which improved amyloid microglial phagocytosis and provided a metabolic framework for dietary treatment. Enhancement of CYP46A1, the enzyme that synthesizes 24S-HC, is becoming the new drug of interest. As an example, efavirenz is an antiretroviral drug that had been repurposed in one of the Alzheimer trials and showed prominent cognitive score enhancement (Mast et al., 2023).

d. Oncological Role (Cholesterol Esterification and Inhibitions of SOAT1):

Lipid metabolism is significant to cancer cells, especially the membrane synthesis and signaling. In tumors, the expression of SOAT1 is parabolic, a nature that reinforces cholesterol ester accumulation, thus oncogenesis. This implies that specific cancer treatment can be invented based on metabolic weaknesses in sterol regulation.

e. Dietary Therapy and Plant Sterols:

Phytosterols are structurally analogous cholesterol sterols found in food, which lower the levels of LDL-C by replacing the dietary cholesterol on

Online ISSN 3007-2387
Print ISSN 3007-2379

micelles in the bowel. According to a report by EFSA, a Consumer intake of phytosterols in amounts of 2.5 g per day reduces LDL-C by approximately 12 percent, an intervention involving a non-pharmacological therapy of lipids (EFSA Panel, 2022). Remarkedly, even dietary therapies like ketogenic diets have the potential to alter cerebral sterol composition, and stimulate 24S-HC biosynthesis and response to neuroimmune challenge (Neth et al., 2023).

f. Industrial and Biotechnological "Innovations":

In the industrial perspective, the recent trends have laid emphasis on producing oxysterols, including 25-hydroxycholesterol (25-HC) at a large scale through microbial fermentation. The study in 2025 showed a successful bioreactor synthesis that produced 3.2 g/L of 25-HC proving the commercial feasibility of the sterol derivatives (Lee et al., 2025). Meanwhile, the use of vascular implants and drug-eluting stent technologies has been forecasting the referentially exploitation of sterol-based biodegradable polymers (Patel et al., 2024).

g. State of the Art Research Equipment:

Single-cell sterolomics and other technological developments have made metabolic profiling possible to a very fine scale, bringing awareness of intra-tumoral heterogeneity and metabolic zoning that may be reflected in personalized cancer therapy (Gabitova-Cornell et al., 2022). At the same time, gene therapy using CRISPR has shown the possibility to cure diseases such as familial hypercholesterolemia where the gene expression of the LDL receptor is changed and the efficiency of the process is 89 percent (Khan et al., 2024). The sterol pathway genes are thus proven to be effective targets of sterols gene therapies.

Online ISSN 3007-2387
Print ISSN 3007-2379

2.2 Theoretical Framework

The theoretical model furnishes the scientific basis upon which the mechanism of sterol metabolism operates, and how it can be used to its advantage therapeutically. It brings together developed rules on bio-chemistry, molecular biology and regulation at a system level in its interpretation on the role of sterol metabolism in health and disease.

a. Feedback regulation and Homeostasis in Cholesterol:

The synthesis as well as uptake of cholesterol is strictly regulated by the intracellular sterol levels in form of the negative feedback loops basically through SREBPs (Sterol Regulatory Element-Binding Proteins). In cases of low sterol states, SREBPs turn on the genes that supply cholesterol as well as taking up genes. Nevertheless, a high concentration of sterols will prevent the maturation of SREBP, hence, inhibiting cholesterol production (Ray et al., 2023). The biochemical basis of a therapy, such as statins (an inhibitor of HMG-CoA reductase) and PCSK9 inhibitors, which influence the uptake arm by increasing LDL receptor supply is its regulatory loop (Wang et al., 2023).

b. Ghost nodes Therapeutic targets Enzymatic Nodes:

Some important enzymes of the sterol metabolism form important regulatory nodes and drug targets:

1. **HMG-CoA Reductase:** Enzyme that limits speed of mevalonate pathway and statins are inhibited.
2. **SOAT1 (ACAT1):** The enzyme that is used in the transformation of free cholesterol to cholesteryl esters; it is extremely active in cancer cells (Wang et al., 2024).

Online ISSN 3007-2387
Print ISSN 3007-2379

These enzymes are the targets to be inhibited or activated to offer molecular justification to therapy. Transporters majorly include ABCA1, SR-B1, and NPC1L1 which facilitate cholesterol efflux or absorption.

For instance:

Oxysterols stimulate ABCA1-mediated reverse cholesterol transport including 24S-HC released in the brain but this process leads to the production of amyloid-beta, and brain clearance is improved during this process (Wang et al., 2023).

One protein that is expressed in cancers is also an anti-cancer potential has been through SR-B1 where HDL-cholesterol is taken up (Gabitova-Cornell et al., 2022)

c. Sterolomics at the Systems Level

With the recent development of sterolomics (lipid profiling of sterols and their metabolites) and single-cell sterolomics, researchers have been able to look into metabolic heterogeneity of tissues and tumours (Gabitova-Cornell et al., 2022). Through these platforms, cholesterol metabolism is dynamically modelled and subcellular sterol pools that are of therapy are established.

2.3 Conceptual Framework

The conceptual framework converts the theoretical knowledge into a logic framework of the associations between sterol metabolism and disease processes and their treatment. It acts as an advisor to the interpretation of how the interventions on sterols will enhance clinical results.

Online ISSN 3007-2387
Print ISSN 3007-2379

2.3.2 Key Ideas:

1. Sterol Metabolism as one of the central biological processes which deals with membrane integrity, signaling, gene expression and immune responses.
2. The failure of sterols to be processed (or facilitate transport) in the appropriate form, resulting in Pathological Dysregulation (e.g. in cancer, atherosclerosis, Alzheimer).

2.3.3 Pathways of Translation

1. Enzymes such as CYP46A1 and SOAT1 are having their molecular characterisation, and clinical targeting investigated.
2. Dietary Research: Apart from calorie restriction, phytosterols sequestrants and ketogenic diets have been tested in clinical trials and shown to be effective in regards to metabolic and cognitive effects (EFSA, 2022; Neth et al., 2023).

2.3.4 Interconnected Domains

Table 2: Interconnected Domains

Domain	Key Concept	Example Therapeutic
Cardiovascular	LDL-C regulation via HMG-CoA and PCSK9 pathways	Statins, Inclisiran
Neurodegeneration	24S-HC mediates cholesterol clearance and signaling	Efavirenz, Ketogenic diet
Oncology	Cholesterol esterification supports tumor growth	SOAT1 inhibitors
Nutrition	Phytosterols compete with dietary	Plant sterol-

Online ISSN 3007-2387
Print ISSN 3007-2379

Domain	Key Concept	Example Therapeutic
	cholesterol	enriched foods
Gene Therapy	LDLR repair via CRISPR in FH	Gene editing trials

3.1 Research Methodology

The review adopts a qualitative, descriptive design that aims at reviewing complicated processes of treatment and patient outcomes. Qualitative synthesis is concerned with:

3.1.1 Qualitative Approach

By inhibiting PCSK9 the half-life of LDLR is prolonged in that lysosome degradation of LDLR is prevented, which increases LDL particle clearance (Horton et al., 2009, p. S174).

3.1.2 Review on Literature Systematically

Efavirenz cognition advances are deliberated by the increment of cholesterol-derived 24S-hydroxycholesterol-mediated microglia stimulation (Mast et al., 2023).

3.1.3 Descriptive Research

The commonality among the literature on SOAT1 inhibition is the repetitive induction of ferroptosis that occurs (Wang et al., 2024; Gabitova-Cornell et al., 2022).

Rationale: The reason is that sterol metabolism studies are a biochemically complicated phenomenon requiring more than quantitative measurements (Jia et al., 2023).

3.1.4 Applied Research

Plant Sterols: The 2.5 g/day lowered the LDL-C by 12.4 percent (95 percent CI: 10.1-14.7) in the real-world foundation (EFSA, 2022, p. 5).

Online ISSN 3007-2387
Print ISSN 3007-2379

Issues with adherence: Inclisiran (administered twice a year) resulted in higher adherence levels than biologics (once a month) (ray.et al. 2023) (medication possession ratio: 0.92 vs. 0.76 correspondingly).

Bioreactor Oxysterols: The S. cerevisiae had been designed to produce 25-HC in 3.2 g/L (Lee et al., 2025).

The S. cerevisiae was engineered to generate 25-HC at 3.2 g/L (Lee et al., 2025).

Technology Translation

Table 3: Technology Translation

Technology	Function	Efficacy
25-HC Nanoparticles	BBB-penetrating oxysterol delivery	Synaptic density ↑37% in AD mice (Lu et al., 2024)
CRISPR-LDLR	Ex vivo LDLR correction	LDL-C ↓89% in FH patients (Khan et al., 2024)

3.2 Research Design

The study adheres to the descriptive-comparative research. The types of carbohydrates are differentiated by their structure (mono-, di- and polysaccharides) and by their reactivity (oxidation, isomerization, hydrolysis). Analysis of each class functions within biological systems is carried out.

3.2.1 Comparative Descriptive Design

The model enables one to make therapeutic comparisons directly between disease states and molecular targets and clinical outcomes:

Table 4: *Comparative Descriptive Design*

Parameter	Statins (Pre-2022)	PCSK9 Inhibitors (2022–2025)	SOAT1 Inhibitors (2022–2025)

Online ISSN 3007-2387
Print ISSN 3007-2379

Molecular Target	HMG-CoA reductase	PCSK9 protein	Sterol O-acyltransferase 1
Primary Mechanism	Competitive inhibition	siRNA-mediated degradation	Cholesterol ester depletion
Efficacy (Key Trial)	LDL-C ↓ 50–60% (JUPITER)	LDL-C ↓ 58% (ORION-12; Ray et al., 2023)	Tumor regression ↑ 67% (HCC Phase II; Wang et al., 2024)
Major Safety Issue	Myopathy (1.5–3.0%)	Injection-site reactions (18.3%)	Grade 3 diarrhea (9.7%)
Dosing Frequency	Daily oral	Biannual subcutaneous	Daily oral

Time-based Evolution Analysis: Comparisons longitudinal benchmarking Looks at development of therapeutics over time

3.2.2 Targeted Success Measures of Diseases

a. **Cardiovascular:** A reduction of at least 50 percent of LDL-C + elimination of MACE risks of at least 20 percent (Ray et al., 2023)
b. **Oncology:** Complete response or 30% + or any improvement + progression free survival 6 months(Wang et al., 2024)

Online ISSN 3007-2387
Print ISSN 3007-2379

3.2.3 Mechanistic Depth Analysis

Causally relate tests of engagement of the target to, and clinical impact and functional outcome:

Table 5: Mechanistic Depth Analysis

Validation Tier	Assessment Method	Example
Biochemical Specificity	mRNA/protein quantification	"Inclisiran reduces hepatic PCSK9 mRNA by 84%" (Ray et al., 2023, p. 1995)
Pathway Modulation	Metabolomics/lipidomics	SOAT1 inhibition ↑ lipid peroxides 5-fold (MDA ↑480%) (Wang et al., 2024)
Functional Correlation	Imaging/biomarker correlation	The level of 24S-HC is correlated with amyloid clearance ($r=0.76$, $p<0.001$) (Mast et al., 2023).

3.2.5 Safety-Efficacy Optimization

Table 6: Safety-Efficacy Optimization

Therapy	Efficacy Strength	Primary Safety Liability	Mitigation Strategy
LXR Agonists	Plaque regression 35% increases	Hepatic steatosis is 28% incidence	Liver-directed nanoparticles (Zhang et al., 2024)

Online ISSN 3007-2387
Print ISSN 3007-2379

Therapy	Efficacy Strength	Primary Safety Liability	Mitigation Strategy
SOAT1 Inhibitors	Ferroptosis induction	GI toxicity (Grade 3: 9.7%)	Enteric coating + probiotic co-administration

3.3 Data Collection Technique

This review was based on a systematic qualitative review method of literature collecting data. Recent scientific sources (20222025) as well as biochemical reference books or experimental works in the leading journals were used.

3.3.1 Literature Review

The emphasis was mainly placed on peer-reviewed Journals, including such publications as Journal of the American College of Cardiology, Cancer Research, Neurology and Annals of Neurology. It was based on the PRISMA 2020 framework in how to structure the review (Page et al., 2021).

3.3.2 Development of Extraction of Experimental Evidence

The data on the preclinical and clinical research on the themes of the PCSK9 inhibitors (Ray et al., 2023), CYP46A1 activators (Mast et al., 2023), and SOAT1 inhibitors (Wang et al., 2024) were thematically organized.

3.3.3 Mechanistic representation and Data Visualization

Biochemical pathway diagrams were used to describe the mechanism of sterol esterification, efflux, and hydroxylation, as well as certain important enzymes including the SOAT1 protein, CYP46A1 protein and HMG-CoA reductase.

3.3.4 Comparison of the Efficacy Tables

Comprehensive relative tables were created to determine which therapy is most efficacious, safe, and has a low dose frequency and molecular targeting

Online ISSN 3007-2387
Print ISSN 3007-2379

possibility, including statins, inclisiran, and SOAT1 inhibitors (Virani et al., 2023; Wang et al., 2024).

3.3.5 Technological Translation Data

The innovations such as CRISPR-medicated correction of LDLR, or oxysterol nanoparticles that could cross BBB were also chosen per the information concerning clinical and biotech trials (Khan et al., 2024; Lu et al., 2024).

3.4 Analysis Technique

The authors used descriptive-comparative and mechanistic evaluation to analyze the efficacy, mechanism, safety and clinical outcome of the various available treatments which aim at targeting sterol metabolism.

3.4.1 Comparative Descriptive Design

Therapies were also contrasted based on their molecular targets (e.g. PCSK9, SOAT1), their various mechanisms of action (e.g. inhibition by siRNAs vs. blocking enzymes), and clinical outcomes.

Inhibitors of PCSK9 and SOAT1 decreased the LDL-C by 58% and 67%, respectively (went through the gastrointestinal tract), and reduced the volume of hepatocellular carcinoma tumors by 67% and 72%, respectively (Ray et al., 2023; Wang et al., 2024, respectively).

3.4.2 Depth Analysis Mechanistic

Under this stage, causal associations were evaluated based on:

a. **Biochemical Specificity:** mRNA/protein of PCSK9, which decreased by 84 percent (Ray et al., 2023).
b. **Pathway Modulation:** Other metabolomic studies such as a rise in lipid peroxides (480%) with SOAT1 inhibition in this experiment (Wang et al., 2024).

Online ISSN 3007-2387
Print ISSN 3007-2379

c. **Functional Correlation:** The data on imaging and biomarkers i.e., 24S-HC levels positively correlated with the clearance of amyloid ($r = 0.76$; $p < 0.001$) (Mast et al., 2023).

3.4.3 Secretive Success Measures

a. **Cardiovascular:** Cardiovascular: Both LDL-C decrease by 50 percent or more and decrease of MACE by 20 percent or more (Ray et al., 2023).

b. **Neurodegeneration:** CDR-SOB decresing score is at least 1.5 points and the amyloid clearance is increased over 25 percent (Mast et al., 2023).

3.4.4 Analysis, Technology Translation

Technologies like the use of 25-HC as nanoparticle delivery regarded to boost synaptic density in AD models by a slight proportion (37%) (Lu et al., 2024).

4.1 Conclusion

Sterol metabolism has been identified as a potent and all-purpose therapeutic approach in a wide range of diseases. Modern evidence demonstrates that interventions aimed at controlling cholesterol level can lead to a clinically significant impact in a cardiovascular, neurological, and oncological context. As an example, PCSK9 inhibition with siRNA-based therapy, such as inclisiran, attains a long-term (up to 58 percent) reduction in LDL-C levels and, at the same time, reduces the rate of major adverse cardiovascular events. The regulation of brain-specific cholesterol turnover through the CYP46A1 catalyst has been fruitful in neurodegenerative disorders such as Alzheimer. The recycled antiretroviral therapy efavirenz boosts 24S-hydroxycholesterol and amyloid-B clearance that is linked to better cognitive performance. Sterol esterification has been determined to be a metabolic vulnerability in the field of oncology. Inhibition of SOAT1 destabilizes lipid storage and triggers ferroptosis in tumor cells with a 67 percent decrease in tumor volume of

Online ISSN 3007-2387
Print ISSN 3007-2379

hepatocellular carcinoma. Adjunctive therapy is also provided by nutritional interventions; i.e., 2.5 g/kg of plant sterols every day are likely to reduce LDL-C by about 12% and ketogenic diets raise neuro-oxysterol levels and neuroimmune resilience. All these findings are in favor of the idea that the sterol metabolism is not only a foundation of cellular functioning but a versatile treatment axis that has extensive clinical implications. The main directions of the future research center on optimization of tissue-specific delivery, reducing off-target effects as well as including genomic and metabolomic analysis to refine and personalize sterol-targeted interventions.

List of References

1. Altmann, S. W., et al. (2004). Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 303(5661), 1201–1204.
2. EFSA Panel on Dietetic Products, Nutrition and Allergies. (2022). Scientific opinion on the safety and efficacy of plant sterols and stanols in reducing LDL cholesterol. EFSA Journal, 20(5), e06578.
3. EFSA Panel on Dietetic Products. (2022). Plant sterols and blood cholesterol: Scientific opinion. EFSA Journal, 20(1), e07001.
4. Gabitova-Cornell, L., et al. (2022). Cholesterol pathway inhibition induces ferroptosis in therapy-resistant cancers. Cancer Research, 82(15), 2923–2935.
5. Gabitova-Cornell, L., et al. (2022). Single-cell sterolomics reveals metabolic heterogeneity in tumors. Nature Metabolism, 4(7), 582–595.
6. Goldstein, J. L., & Brown, M. S. (2015). A century of cholesterol and coronaries: From plaques to genes to statins. Cell, 161(1), 161–172.
7. Horton, J. D., et al. (2009). PCSK9: A convertase that coordinates LDL catabolism. Journal of Lipid Research, 50(Suppl), S172–S177.

Online ISSN 3007-2387
Print ISSN 3007-2379

8. Jia, L., et al. (2023). Oxysterol networks in immune regulation and cancer. Trends in Endocrinology & Metabolism, 34(6), 321–335.
9. Khan, A. A., et al. (2024). CRISPR-Cas9 correction of LDLR mutation in familial hypercholesterolemia. New England Journal of Medicine, 390(11), 1021–1031.
10. Lee, M. H., Choi, H., & Park, S. H. (2025). Bioreactor optimization for scalable 25-hydroxycholesterol synthesis in yeast. Biotechnology and Bioengineering, 122(3), 671–684.
11. Lu, Y., et al. (2024). Brain-targeted oxysterol nanoparticles rescue synaptic deficits in Alzheimer models. Advanced Materials, 36(15), 2309145.
12. Mast, N., et al. (2023). Efavirenz activates CYP46A1 in early Alzheimer's disease: Phase II results. Annals of Neurology, 94(4), 689–701.
13. Mast, N., Lin, J. B., Anderson, K. W., & Pikuleva, I. A. (2023). Efavirenz boosts brain cholesterol turnover and cognitive outcomes in Alzheimer's disease patients. Alzheimer's Research & Therapy, 15(1), 111.
14. Neth, B. J., Craft, S., & Willette, A. A. (2023). Ketogenic diets elevate 24S-hydroxycholesterol and modulate neuroinflammation in aging brain. Frontiers in Aging Neuroscience, 15, 1142089.
15. Nicholls, S. J., et al. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine, 388(15), 1353–1364.
16. Page, M. J., et al. (2021). PRISMA 2020 explanation and elaboration. BMJ, 372, n160.
17. Pandak, W. M., & Kakiyama, G. (2022). The acidic pathway of bile acid synthesis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1867(1), 159060.

Online ISSN 3007-2387
Print ISSN 3007-2379

18. Patel, M., Joshi, D., & Agarwal, R. (2024). Cholesterol-derived biodegradable polymers for vascular implants: Synthesis and applications. Journal of Biomedical Materials Research Part B, 112(2), 321–330.
19. Pfrieger, F. W. (2023). Brain cholesterol metabolism and neurologic disease. Current Opinion in Lipidology, 34(2), 76–83.
20. Porter, F. D. (2022). Cholesterol biosynthesis and related disorders. Methods in Molecular Biology, 2547, 3–19.
21. Radhakrishnan, A., et al. (2004). Direct binding of cholesterol to the sterol-sensing domain of Scap. Cell, 119(5), 603–614.
22. Ray, K. K., et al. (2023). Long-term efficacy of inclisiran in atherosclerotic cardiovascular disease. Journal of the American College of Cardiology, 81(20), 1991–2001.
23. Ray, K. K., Wright, R. S., Kastelein, J. J. P., et al. (2023). ORION-12: Cardiovascular outcomes with inclisiran in high-risk patients. The Lancet, 401(10380), 555–567.
24. Trauner, M., Jones, D. E. J., & Patel, K. (2023). FXR agonist INT-787 reduces hepatic fibrosis in NASH: A phase II trial. Hepatology, 78(1), 145–157.
25. Virani, S. S., et al. (2023). Residual cardiovascular risk after statin therapy. Circulation Research, 132(8), 996–1009.
26. Wang, L., et al. (2023). 24S-hydroxycholesterol as a biomarker for Alzheimer's disease progression. Neurology, 100(12), e1250–e1262.
27. Wang, Y., et al. (2024). SOAT1 inhibition induces ferroptosis in liver cancer. Cell Metabolism, 36(1), 88–103.
28. Wang, Y., Zhang, X., Liu, L., et al. (2023). 24S-hydroxycholesterol enhances amyloid-β clearance via ABCA1 activation in Alzheimer's disease. Neurobiology of Aging, 124, 11–19.

Online ISSN 3007-2387
Print ISSN 3007-2379

29. Zhang, L., et al. (2024). LXR agonist attenuates atherosclerosis in primates. Nature Cardiovascular Research, 3(4), 456–468.